Custom Criteria for
BlueCross Blue Shield of Rhode Island Commercial

NPLATE® (romiplostim)

GPI CODING:

8240506000****

DESCRIPTION:

Romiplostim is an injectable thrombopoietin-mimetic Fc-peptide fusion protein (peptibody) produced by recombinant DNA technology in Escherichia coli. ETPO receptor agonists bind to the human TPO receptor to initiate a signaling cascade similar (but not identical) to that of endogenous TPO, inducing proliferation and differentiation of megakaryocytes from bone marrow progenitor cells leading to an increase in platelet production.

APPROVAL DURATION:

Initial approval: 6 months
Renewal: 3-12 months

CRITERIA FOR NPLATE

I. Patient has a diagnosis of chronic immune (idiopathic) thrombocytopenic purpura (ITP) AND
II. Patient has thrombocytopenia that requires treatment AND
III. Patient had an insufficient response, intolerance, or contraindication to corticosteroids or immune globulin
OR
IV. Patient had an inadequate response or contraindication to a splenectomy